Clinical trial successfully repurposes cancer drug for hereditary bleeding disorder
A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary hemorrhagic telangiectasia (HHT), the world's second-most-common inherited bleeding disorder, affects approximately 1-in-5,000 people and can have life-threatening complications, but there are currently no U.S. FDA-approved drugs to treat HHT.
https://www.sciencedaily.com/releases/2024/09/240918214046.htm
Science Daily /
npub1zy…0g584
2024-09-19 04:15:12
Author Public Key
npub1zyta2gptl27agsjmwqqynml85s9ffr5krvcqfgmhwxzm69glwycs30g584Seen on
wss://nos.lolPublished at
2024-09-19 04:15:12Event JSON
{
"id": "b41a0a07bf452e7e4b7f26ca5f663966986fb15b2bc7f810c983f8f26c2698ae",
"pubkey": "1117d5202bfabdd4425b700049efe7a40a948e961b3004a3777185bd151f7131",
"created_at": 1726712112,
"kind": 1,
"tags": [
[
"guid",
"https://www.sciencedaily.com/releases/2024/09/240918214046.htm"
]
],
"content": "Clinical trial successfully repurposes cancer drug for hereditary bleeding disorder\n\nA drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary hemorrhagic telangiectasia (HHT), the world's second-most-common inherited bleeding disorder, affects approximately 1-in-5,000 people and can have life-threatening complications, but there are currently no U.S. FDA-approved drugs to treat HHT.\n\nhttps://www.sciencedaily.com/releases/2024/09/240918214046.htm",
"sig": "a46c5164278260c8ddb9e11df72c414ed60900d7761757c9fb620bc2ad2380c829d4782baa989f428b56cee8a37f436ff43d874704f826d2c4fe8865fff04781"
}